|
|
MSC治疗新冠病毒引起PF的研究进展
|
Abstract:
新冠疫情在全球的大流行，使感染人数日渐增多的同时，新冠后遗症所致的肺纤维化患者数量也逐渐增加。常规的新冠肺炎治疗手段对于延缓肺纤维化进程的效果有限。此时，间充质干细胞因其低免疫原性和优秀的免疫调节能力成为逆转肺纤维化的新的治疗手段，进入了研究者们的视野。文章对新冠肺炎造成的肺纤维化的原理、间充质干细胞的来源和应用、间充质干细胞治疗肺纤维化的方法和原理进行综述，从直接修复、固有免疫、适应性免疫、抑制细胞间信号、增加抗纤维化因子的表达等方面阐述治疗肺纤维化的机制。旨在探讨这种新兴的治疗方式对于治疗肺纤维化的效果。此外，文中还讨论了中药联合间充质干细胞治疗新冠肺炎的可能性，探讨了干细胞治疗方案的挑战。
The global pandemic of COVID-19 (Corona Virus Disease 2019) is increasing the number of infections while the number of patients with pulmonary fibrosis due to the sequelae of COVID-19 is also gradually increasing. Conventional treatments for COVID-19 have limited effect on slowing down the process of pulmonary fibrosis. At this time, mesenchymal stem cells have entered the researchers’ field of vision because of their low immunogenicity and excellent immunomodulatory ability, which are expected to become a new therapeutic means to reverse pulmonary fibrosis. In this paper, we review the principles of pulmonary fibrosis caused by neococcal pneumonia, the sources and clinical applications of MSCs, and the methods and principles of MSC therapy for pulmonary fibrosis, and describe the mechanisms of treating pulmonary fibrosis in terms of direct repair, intrinsic immunity, adaptive immunity, inhibition of intercellular signaling, and increase in the expression of antifibrotic factors. It aims to explore the effect of this emerging therapeutic modality for the treatment of pulmonary fibrosis. In addition, the paper discusses the possibility of combining traditional Chinese medicine with mesenchymal stem cells for the treatment of neocoronitis and explores the challenges of stem cell therapy programs.
| [1] | Forchette, L., Sebastian, W. and Liu, T. (2021) A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics. Current Medical Science, 41, 1037-1051. https://doi.org/10.1007/s11596-021-2395-1 |
| [2] | Huang, C., Wang, Y., Li, X., et al. (2020) Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. The Lancet, 395, 497-506. https://doi.org/10.1016/S0140-6736(20)30183-5 |
| [3] | 李红园, 朱洁云, 钟枝梅, 等. 重症新型冠状病毒肺炎(COVID-19)患者基础疾病患病率的Meta分析[J]. 疑难病杂志, 2020, 19(6): 541-547. |
| [4] | 李运江, 叶云峰, 宣伟玲, 等. 有无基础疾病的新型冠状病毒肺炎患者首次胸部高分辨率CT表现比较[J]. 浙江医学, 2021, 43(14): 1575-1578,1585. |
| [5] | 仕丽, 丁欢, 王檀, 等. 134例合并不同基础疾病新型冠状病毒肺炎患者转重率分析[J]. 吉林中医药, 2021, 41(11): 1458-1461. |
| [6] | 张丽娜, 彭倩宜. 新型冠状病毒感染重症救治专家建议[J]. 实用休克杂志(中英文), 2022, 6(6): 363-366. |
| [7] | 杜淑华, 刘莹, 梁桐, 等. 重症新型冠状病毒肺炎患者的临床特征分析[J]. 中国急救医学, 2020, 40(10): 993-997. |
| [8] | 苏兵, 赵东, 曾照富, 等. 新型冠状病毒肺炎死亡病例临床特点及危险因素分析[J]. 临床内科杂志, 2020, 37(7): 531-534. |
| [9] | Shang, J., Ye, G., Shi, K., et al. (2020) Structural Basis of Receptor Recognition by SARS-CoV-2. Nature, 581, 221-224. https://doi.org/10.1038/s41586-020-2179-y |
| [10] | Muus, C., Luecken, M.D., Eraslan, G., et al. (2021) Single-Cell Meta-Analysis of SARS-CoV-2 Entry Genes across Tissues and Demographics. Nature Medicine, 27, 546-559. https://doi.org/10.1038/s41591-020-01227-z |
| [11] | Hikmet, F., Méar, L., Edvinsson, ？., et al. (2020) The Protein Expression Profile of ACE2 in Human Tissues. Molecular Systems Biology, 16, E9610. https://doi.org/10.15252/msb.20209610 |
| [12] | Puelles, V.G., Lütgehetmann, M., Lindenmeyer, M.T., et al. (2020) Multiorgan and Renal Tropism of SARS-CoV-2. The New England Journal of Medicine, 383, 590-592. https://doi.org/10.1056/NEJMc2011400 |
| [13] | Harmer, D., Gilbert, M., Borman, R., et al. (2002) Quantitative MRNA Expression Profiling of ACE2, a Novel Homologue of Angiotensin Converting Enzyme. FEBS Letters, 532, 107-110. https://doi.org/10.1016/S0014-5793(02)03640-2 |
| [14] | 张晓晴, 李树仁, 牛绍乾. ACE2与新型冠状病毒肺炎[J]. 国际心血管病杂志, 2020, 47(2): 68-70. |
| [15] | Shen, H., Zhang, N., Liu, Y., et al. (2022) The Interaction Between Pulmonary Fibrosis and COVID-19 and the Application of Related Anti-Fibrotic Drugs. Frontiers in Pharmacology, 12, Article 805535. https://doi.org/10.3389/fphar.2021.805535 |
| [16] | Wynn, T.A. (2007) Common and Unique Mechanisms Regulate Fibrosis in Various Fibroproliferative Diseases. Frontiers in Pharmacology, 117, 524-529. https://doi.org/10.1172/JCI31487 |
| [17] | Tomasek, J.J., Gabbiani, G., Hinz, B., et al. (2002) Myofibroblasts and Mechano-Regulation of Connective Tissue Remodelling. Nature Reviews Molecular Cell Biology, 3, 349-363. https://doi.org/10.1038/nrm809 |
| [18] | Friedman, S.L. (2004) Mechanisms of Disease: Mechanisms of Hepatic Fibrosis and Therapeutic Implications. Nature Clinical Practice Gastroenterology & Hepatology, 1, 98-105. https://doi.org/10.1038/ncpgasthep0055 |
| [19] | Wynn, T.A. (2011) Integrating Mechanisms of Pulmonary Fibrosis. Journal of Experimental Medicine, 208, 1339-1350. https://doi.org/10.1084/jem.20110551 |
| [20] | 王苏丹, 李宏军, 张岩岩. 新型冠状病毒肺炎患者胸部CT影像动态变化及临床特征分析[J]. 北京医学, 2022, 44(10): 907-913. |
| [21] | 北京协和医院新型冠状病毒感染诊疗多学科专家组. 北京协和医院成人新型冠状病毒感染实用诊疗建议(2023) [J]. 协和医学杂志, 2023, 14(1): 50-59. |
| [22] | 徐若男, 谢云波, 孟繁平, 等. 新型冠状病毒肺炎临床治疗及间充质干细胞治疗的进展[J]. 中华传染病杂志, 2020, 38(8): 528-532. |
| [23] | Meng, F., Xu, R., Wang, S., et al. (2020) Human Umbilical Cord-Derived Mesenchymal Stem Cell Therapy in Patients with COVID-19: A Phase 1 Clinical Trial. Signal Transduction and Targeted Therapy, 5, Article No. 172. https://doi.org/10.1038/s41392-020-00286-5 |
| [24] | Fu, X., Liu, G., Halim, A., et al. (2019) Mesenchymal Stem Cell Migration and Tissue Repair. Cells, 8, Article 784. https://doi.org/10.3390/cells8080784 |
| [25] | 赵璇, 张毅. 间充质干细胞——新冠病毒肺炎相关急性呼吸窘迫综合征潜在的治疗选择[J]. 工程(英文), 2020, 6(10): 1073-1075. |
| [26] | Chen, J., Hu, C., Chen, L., et al. (2020) Clinical Study of Mesenchymal Stem Cell Treatment for Acute Respiratory Distress Syndrome Induced by Epidemic Influenza a (H7N9) Infection: A Hint for COVID-19 Treatment. Engineering, 6, 1153-1161. https://doi.org/10.1016/j.eng.2020.02.006 |
| [27] | Friedenstein, A.J., Gorskaja, J.F. and Kulagina, N.N. (1976) Fibroblast Precursors in Normal and Irradiated Mouse Hematopoietic Organs. Experimental Hematology, 4, 267-274. |
| [28] | 傅文玉, 路艳蒙, 朴英杰. 人骨髓间充质干细胞的培养及多能性研究[J]. 中华血液学杂志, 2002, 23(4): 202-2045. |
| [29] | 廖娟, 文彬, 邓鑫. 细胞因子风暴在新型冠状病毒肺炎病情加重中的作用研究进展[J]. 细胞与分子免疫学杂志, 2020, 36(10): 941-947. |
| [30] | 卢昆, 耿仕涛, 夏婧, 等. 间充质干细胞在调节新型冠状病毒肺炎患者免疫功能中的应用[J]. 中华重症医学电子杂志(网络版), 2021, 7(1): 55-65. |
| [31] | Laffey, J.G. and Matthay, M.A. (2017) Fifty Years of Research in ARDS. Cell-Based Therapy for Acute Respiratory Distress Syndrome. Biology and Potential Therapeutic Value. American Journal of Respiratory and Critical Care Medicine, 196, 266-273. https://doi.org/10.1164/rccm.201701-0107CP |
| [32] | Wynn, T.A. (2008) Cellular and Molecular Mechanisms of Fibrosis. The Journal of Pathology, 214, 199-210. https://doi.org/10.1002/path.2277 |
| [33] | 徐秀萍. AngⅡ-AT2R介导间充质干细胞向急性肺损伤小鼠肺组织归巢的机制和效应研究[D]: [博士学位论文]. 南京: 东南大学, 2018. |
| [34] | 王媞尔, 史明霞. 间充质干细胞旁分泌作用的研究进展[J]. 实用医学杂志, 2021, 37(13): 1651-1654. |
| [35] | Spaggiari, G.M., Capobianco, A., Abdelrazik, H., et al. (2008) Mesenchymal Stem Cells Inhibit Natural Killer-Cell Proliferation, Cytotoxicity, and Cytokine Production: Role of Indoleamine 2,3-Dioxygenase and Prostaglandin E2. Blood, 111, 1327-1333. https://doi.org/10.1182/blood-2007-02-074997 |
| [36] | Gharibi, T., Ahmadi, M., Seyfizadeh, N., et al. (2015) Immunomodulatory Characteristics of Mesenchymal Stem Cells and Their Role in the Treatment of Multiple Sclerosis. Cellular Immunology, 293, 113-121. https://doi.org/10.1016/j.cellimm.2015.01.002 |
| [37] | 李小丽, 王炎, 朱钟慧, 等. 间充质干细胞的旁分泌作用在组织损伤修复中的研究进展[J]. 实用医学杂志, 2018, 34(22): 3663-3666. |
| [38] | 钟艺, 舒畅, 符州. 间充质干细胞通过旁分泌抑制肺纤维化的分子机制[J]. 重庆医学, 2014(25): 3376-3379. |
| [39] | 杨静, 胡华钟, 张书勤, 等. 脐带间充质干细胞来源的外泌体通过抑制上皮间质转化缓解肺纤维化[J]. 南方医科大学学报, 2020, 40(7): 988-994. |
| [40] | 刘莉, 王娜, 许迪魁, 等. 中药制剂治疗新冠肺炎的机制[J]. 生命的化学, 2022, 42(12): 2222-2230. |
| [41] | 中华人民共和国国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第九版) [J]. 传染病信息, 2022, 35(2): 97-106. |
| [42] | 马林纳, 王瑞, 苗明三. 基于数据挖掘的治疗肺纤维化中药用药规律分析[J]. 中草药, 2020, 51(6): 1406-1411. |
| [43] | 柯诗文, 岳学普, 李少峰, 等. 间充质干细胞来源的外泌体: 中药治疗肺病新视角[J]. 中华中医药学刊, 2020, 38(1): 132-135. |
| [44] | 潘小龙, 樊飞燕, 应春苗, 等. 中药抑制间充质干细胞衰老的作用及机制[J]. 中国组织工程研究, 2024, 28(7): 1091-1098. |
| [45] | 陈祖祥, 葛彦志, 范梦强, 等. 不同频次调髓中药对人脐带间充质干细胞的作用[J]. 中华骨与关节外科杂志, 2021, 14(7): 638-643. |
| [46] | 华亮, 周蜜, 迮侃, 等. 间充质干细胞治疗银屑病的机制与中医药研究[J]. 世界临床药物, 2019, 40(11): 806-810. |
| [47] | 潘小龙, 孙世标, 魏智慧, 等. 中药联合骨髓间充质干细胞治疗缺血性脑卒中作用及机制研究进展[J]. 中国实验方剂学杂志, 2022, 28(15): 248-258. |
| [48] | 李世梅, 王黎明, 李铭, 等. 中药前期干预脐带间充质干细胞治疗类风湿关节炎临床疗效观察[J]. 陕西中医, 2015, 36(1): 26-28. |
| [49] | 蒋杨, 陈博, 王贤君, 等. 人脐带间充质干细胞治疗肺部疾病的研究与应用进展[J]. 临床肺科杂志, 2022, 27(1): 124-129. |
| [50] | Szydlak, R. (2021) Biological, Chemical and Mechanical Factors Regulating Migration and Homing of Mesenchymal Stem Cells. World Journal of Stem Cells, 13, 619-631. https://doi.org/10.4252/wjsc.v13.i6.619 |
